Although prior evidence supports consistent CLL-1 expression in AML, the current in vitro findings require future in vivo studies and evaluation using diverse patient samples to fully establish the aptamer’s therapeutic potential and clinical translatability. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.